About
Our Mission
Leadership
Partners
Our Technologies
TALEN® Technology
Gene Editing
PulseAgile Technology
Patents
Pipeline
Products
Clinical Indications
Manufacturing
Investors
Press Releases
Corporate presentation & ESG report
Scientific Presentations
Scientific Publications
Events and Webcasts
2021 Cellectis Innovation Days
Stock Information
Corporate Governance
Governance Documents
Board of Directors & Committee Members
Shareholders Meeting
SEC Filings
Contact
IR Inquiries
Email Alerts
Investor FAQ
Careers
Our Culture
Job Opportunities
Contact us
fr
Press Releases
Our latest news and press releases
Press releases
Corporate presentation
Scientific Presentations
Scientific Publications
Events and webcasts
Stock information
SEC filings
Financial Statements
Regulated information
Voting Rights & Share Capital
ATM Program
General meetings
Governance
The board and committee members
Corporate governance documents
FAQ
IR Inquiry
All
2024
2023
2022
2021
2020
2019
18
Feb 2022
15:22 E.S.T.
Calyxt Announces Pricing of Offering of Common Stock and Warrants and Updates Business and Risk Factor Disclosure
Read more
10
Feb 2022
16:44 E.S.T.
Cellectis Appoints Bing Wang, PhD, MBA as Chief Financial Officer
Read more
10
Jan 2022
16:30 E.S.T.
Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials
Read more
04
Jan 2022
14:37 E.S.T.
Cellectis Provides Business Objectives for 2022 and Updates its Corporate Presentation
Read more
11
Dec 2021
10:11 E.S.T.
Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting
Read more
18
Nov 2021
13:44 E.S.T.
Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China
Read more
Prev
15
16
17
18
19
Next